JPWO2022037531A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022037531A5 JPWO2022037531A5 JP2023511960A JP2023511960A JPWO2022037531A5 JP WO2022037531 A5 JPWO2022037531 A5 JP WO2022037531A5 JP 2023511960 A JP2023511960 A JP 2023511960A JP 2023511960 A JP2023511960 A JP 2023511960A JP WO2022037531 A5 JPWO2022037531 A5 JP WO2022037531A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- seq
- binding fragment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010828886 | 2020-08-17 | ||
| CN202010828886.4 | 2020-08-17 | ||
| CN202011152518.9 | 2020-10-23 | ||
| CN202011152518 | 2020-10-23 | ||
| PCT/CN2021/112771 WO2022037531A1 (zh) | 2020-08-17 | 2021-08-16 | 抗cd73的抗体及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538369A JP2023538369A (ja) | 2023-09-07 |
| JP2023538369A5 JP2023538369A5 (https=) | 2024-08-26 |
| JPWO2022037531A5 true JPWO2022037531A5 (https=) | 2024-08-26 |
Family
ID=80283259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023511960A Pending JP2023538369A (ja) | 2020-08-17 | 2021-08-16 | 抗ｃｄ７３抗体とその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240218074A1 (https=) |
| EP (1) | EP4197555A4 (https=) |
| JP (1) | JP2023538369A (https=) |
| CN (1) | CN114075289B (https=) |
| AU (1) | AU2021326889A1 (https=) |
| CA (1) | CA3191745A1 (https=) |
| WO (1) | WO2022037531A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021087463A1 (en) * | 2019-11-01 | 2021-05-06 | Corvus Pharmaceuticals, Inc. | Immunomodulatory anti-cd73 antibodies and uses thereof |
| WO2023206242A1 (zh) * | 2022-04-28 | 2023-11-02 | 江苏中新医药有限公司 | 无钩状效应的抗人cd73单克隆抗体 |
| CN117304316A (zh) * | 2022-06-22 | 2023-12-29 | 复旦大学 | 靶向cd73的纳米抗体及纳米抗体-药物偶联物、其制备方法和用途 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO2016131950A1 (en) * | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
| IL250579B2 (en) * | 2014-10-10 | 2023-05-01 | Innate Pharma | blocking cd73 |
| DK3218406T4 (da) * | 2014-11-10 | 2024-12-09 | Medimmune Ltd | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf |
| EP3218407A1 (en) * | 2014-11-11 | 2017-09-20 | Medimmune Limited | Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof |
| MY189836A (en) * | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| CN104558137A (zh) * | 2015-01-15 | 2015-04-29 | 浙江欧诗漫生物股份有限公司 | 一种珍珠蛋白的制备方法及该方法制备得到的水溶性珍珠蛋白和酸溶性珍珠蛋白 |
| US11130817B2 (en) * | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| WO2017100670A1 (en) * | 2015-12-09 | 2017-06-15 | Corvus Pharmaceuticals, Inc. | Humanized anti-cd73 antibodies |
| KR20230038311A (ko) * | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| US11180554B2 (en) * | 2016-12-13 | 2021-11-23 | Astellas Pharma Inc. | Anti-human CD73 antibody |
| EP3383916B1 (en) * | 2017-01-24 | 2022-02-23 | I-Mab Biopharma US Limited | Anti-cd73 antibodies and uses thereof |
| WO2018215535A1 (en) * | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
| CN118307674A (zh) * | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| CN110240654A (zh) * | 2018-03-07 | 2019-09-17 | 复旦大学 | 结合cd73的抗体-药物偶联物 |
| TWI823906B (zh) * | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
| KR102804816B1 (ko) * | 2018-03-09 | 2025-05-09 | 페인스 테라퓨틱스 인코포레이티드 | 항-cd73 항체 및 이의 용도 |
-
2021
- 2021-08-16 EP EP21857625.4A patent/EP4197555A4/en active Pending
- 2021-08-16 AU AU2021326889A patent/AU2021326889A1/en active Pending
- 2021-08-16 CA CA3191745A patent/CA3191745A1/en active Pending
- 2021-08-16 WO PCT/CN2021/112771 patent/WO2022037531A1/zh not_active Ceased
- 2021-08-16 US US18/021,167 patent/US20240218074A1/en active Pending
- 2021-08-16 CN CN202110939980.1A patent/CN114075289B/zh active Active
- 2021-08-16 JP JP2023511960A patent/JP2023538369A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101671452B1 (ko) | 항ｒｓｖ ｇ 단백질 항체 | |
| US9861696B2 (en) | Monoclonal antibodies for Ebola and Marburg viruses | |
| RU2766586C2 (ru) | Фармацевтическая композиция для лечения и/или предупреждения злокачественной опухоли | |
| JP2017518958A (ja) | 免疫原性グリコペプチドに対する抗体、それを含む組成物、及びそれらの使用 | |
| KR20180110089A (ko) | Il-4r 길항제를 투여함으로써 백신의 효능을 향상시키는 방법 | |
| EA034767B1 (ru) | Человеческие антитела к белку f респираторного синцитиального вируса и способы их применения | |
| EP3220947B1 (en) | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof | |
| EP3360896B1 (en) | Antibody to hepatitis b surface antigen and use thereof | |
| CN116785427B (zh) | 呼吸道合胞病毒特异性结合分子的用途 | |
| US9381237B2 (en) | Neutralizing immunogen (NimIV) of rhinovirus and its uses for vaccine applications | |
| JPWO2022037531A5 (https=) | ||
| JPWO2021090062A5 (https=) | ||
| JPWO2022090353A5 (https=) | ||
| CN114773461B (zh) | 乙型脑炎病毒抗体1d11及其应用 | |
| CN112996540A (zh) | 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途 | |
| US20220340658A1 (en) | NEUTRALIZING ANTI-SARS-CoV-2 ANTIBODIES AND USE THEREOF | |
| AU2021403263B2 (en) | Bispecific antibody for specifically neutralizing tgf-β signal of helper t cell, and pharmaceutical combination and use thereof | |
| JPWO2019147867A5 (https=) | ||
| RU2817696C1 (ru) | Моноклональное антитело iC1 и его антигенсвязывающий фрагмент, селективно связывающие рецептор-связывающий домен Spike-белка вируса SARS-CoV-2, обладающие вируснейтрализующей активностью | |
| RU2817697C1 (ru) | Моноклональное антитело iC2 и его антигенсвязывающий фрагмент, селективно связывающие рецептор-связывающий домен Spike-белка вируса SARS-CoV-2, обладающие вируснейтрализующей активностью | |
| US20220289827A1 (en) | Neutralizing antibodies to sars-cov-2 and its variants | |
| US20240218056A1 (en) | Nucleocapsid-specific antibodies and methods for the treatment and prevention of sars-cov-2 infection therewith | |
| TW202229333A (zh) | 冠狀病毒結合分子及其使用方法 | |
| WO2023131262A1 (zh) | 特异性结合SARS-CoV-2的抗原结合蛋白 | |
| JPWO2023079485A5 (https=) |